24 July 2019

Contents

Editorial

• HTB 24 July 2019 online: first reports from IAS 2019

Special reports

• Fit for purpose 2019 – PDF

Conference reports

• 10th IAS Conference on HIV Science (IAS 2019) in Mexico City

• Dolutegravir neural tube defect risk declines but still slightly higher than with other antiretrovirals

• WHO recommends dolutegravir-based ART regimens for all

• High rates of viral suppression with low dose efavirenz in pregnant Zambian women

• First viral load results for capsid inhibitor GS-6207: mean –2.2 log reduction at day 10

• Islatravir (MK-8591) with doravirine plus lamivudine: 24 week results

• Dual therapy with islatravir (MK-8591) plus doravirine: 24 week results as switch strategy

• Fostemsavir: 96-week follow-up in people with multi-drug resistance

• Dolutegravir/lamivudine dual therapy non-inferior to triple ART at week-96

• Switching to dolutegravir/lamivudine dual therapy is non-inferior to TAF-based triple therapy at week-48 in TANGO study

• Islatravir (MK-8591) implant sustains HIV PrEP protection for more than one year

PDFs

• 24 July 2019 vol 20 no 9